
Sign up to save your podcasts
Or


Dr. Jason Crowell talks with 46brooklyn Research CEO Antonio Ciaccia about how Medicare Part D has hidden the benefits of generic competition for Tecfidera, a disease-modifying therapy for multiple sclerosis. Read the full article at 46brooklyn.com.
By American Academy of Neurology4.7
283283 ratings
Dr. Jason Crowell talks with 46brooklyn Research CEO Antonio Ciaccia about how Medicare Part D has hidden the benefits of generic competition for Tecfidera, a disease-modifying therapy for multiple sclerosis. Read the full article at 46brooklyn.com.

320 Listeners

497 Listeners

51 Listeners

288 Listeners

3,337 Listeners

13 Listeners

1,154 Listeners

22 Listeners

194 Listeners

361 Listeners

513 Listeners

133 Listeners

181 Listeners

370 Listeners

79 Listeners